Cystic fibrosis classification: Difference between revisions
| Line 33: | Line 33: | ||
==Classification== | ==Classification== | ||
Cystic fibrosis may be classified according to CFTR protein function abnormality:<ref name="pmid23776378">{{cite journal |vauthors=Burney TJ, Davies JC |title=Gene therapy for the treatment of cystic fibrosis |journal=Appl Clin Genet |volume=5 |issue= |pages=29–36 |year=2012 |pmid=23776378 |pmc=3681190 |doi=10.2147/TACG.S8873 |url=}}</ref> | Cystic fibrosis may be classified according to CFTR protein function abnormality:<ref name="pmid23776378">{{cite journal |vauthors=Burney TJ, Davies JC |title=Gene therapy for the treatment of cystic fibrosis |journal=Appl Clin Genet |volume=5 |issue= |pages=29–36 |year=2012 |pmid=23776378 |pmc=3681190 |doi=10.2147/TACG.S8873 |url=}}</ref><ref name="pmid12606185">{{cite journal |vauthors=Ratjen F, Döring G |title=Cystic fibrosis |journal=Lancet |volume=361 |issue=9358 |pages=681–9 |year=2003 |pmid=12606185 |doi=10.1016/S0140-6736(03)12567-6 |url=}}</ref> | ||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="3" |Cystic fibrosis classification according to CFTR protein function abnormality | ! colspan="3" |Cystic fibrosis classification according to CFTR protein function abnormality | ||
| Line 64: | Line 64: | ||
|Decreased half-life | |Decreased half-life | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 19:52, 9 February 2018
|
Cystic fibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cystic fibrosis classification On the Web |
|
American Roentgen Ray Society Images of Cystic fibrosis classification |
|
Risk calculators and risk factors for Cystic fibrosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
Cystic fibrosis may be classified according to CFTR protein function abnormality:[1][2]
| Cystic fibrosis classification according to CFTR protein function abnormality | ||
|---|---|---|
| Class | Type of abnormality | Features |
| Class 1 | Lack of production | Most common mutations (Class 2 is the most common mutation worldwide)
Associated with pancreatic insufficiency |
| Class 2 | Failure to reach the site of action due to misfolding | |
| Class 3 | Defects in gating | |
| Class 4 | Conductance | Rarer mutations
Typically do not have pancreatic insufficiency |
| Class 5 | Abnormally low channel numbers | |
| Class 6 | Decreased half-life | |
References
- ↑ Burney TJ, Davies JC (2012). "Gene therapy for the treatment of cystic fibrosis". Appl Clin Genet. 5: 29–36. doi:10.2147/TACG.S8873. PMC 3681190. PMID 23776378.
- ↑ Ratjen F, Döring G (2003). "Cystic fibrosis". Lancet. 361 (9358): 681–9. doi:10.1016/S0140-6736(03)12567-6. PMID 12606185.